ABILITY OF 3-CARBOXYSALSOLINOL TO PRODUCE ETHANOL-LIKE DISCRIMINATION IN RATS
Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
Schechter M D
Psychopharmacology
1980
1980
Journal Article
<a href="http://doi.org/10.1007/bf00428115" target="_blank" rel="noreferrer noopener">10.1007/bf00428115</a>
Approaching A Consensus Cognitive Battery For Clinical Trials In Schizophrenia: The Nimh-matrics Conference To Select Cognitive Domains And Test Criteria
cognition; cognitive assessment; cognitive enhancement; impairment; memory; neural basis; neurocognition; neurocognitive deficits; neuroleptic-naive; neuropsychological function; Neurosciences & Neurology; performance; Psychiatry; psychopharmacology; risperidone; schizophrenia; siblings; thought-disorder
To stimulate the development of new drugs for the cognitive deficits of schizophrenia, the National Institute of Mental Health (NIMH) establisbed the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative. This article presents an overview of decisions from the first MATRICS consensus conference . The goals of the meeting were to 1) the cognitive domains that should be represented in a consensus cognitive battery and 2) prioritize key criteria, for selection of tests for the battery. Seven cognitive domains were selected based on a review of the literatum and input from experts: working memory, attention/vigilance, verbal learning and memory, visual learning and memory. Reasoning and problem solving, speed of processing, and social cognition. Based on discussions at this meeting, five criteria were considered essential for test selection: good test-retest reliability high utility as a repeated measure, relationship to functional outcome, potential response to pharmacologic agents, and practicality/tolerability. The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizopbrenia.
Green M F; Nuechterlein K H; Gold J M; Barch D M; Cohen J; Essock S; Fenton W S; Frese F; Goldberg T E; Heaton R K; Keefe R S E; Kern R S; Kraemer H; Stover E; Weinberger D R; Zalcman S; Marder S R
Biological Psychiatry
2004
2004-09
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.biopsych.2004.06.023" target="_blank" rel="noreferrer noopener">10.1016/j.biopsych.2004.06.023</a>
COMPARISON OF NORFENFLURAMINE (NF) DISCRIMINATION IN DRUG (NF)-DRUG (AMPHETAMINE) AND DRUG (NF)-SALINE TRAINED RATS
Psychiatry; Neurosciences & Neurology; Pharmacology & Pharmacy
Boja J W; Schechter M D
Psychopharmacology
1986
1986
Journal Article or Conference Abstract Publication
n/a
Differences in response to the aversive properties and activity effects of low dose ethanol in LAS and HAS selectively bred rats.
Animals; Avoidance Learning/*drug effects; Conditioning; Dose-Response Relationship; Drug; Ethanol/*pharmacology; Motor Activity/drug effects; Operant/drug effects; Rats; Sleep/drug effects; Species Specificity
Rats selectively bred for high alcohol sleep times (HAS) and those that are less affected (LAS) by hypnotic doses (3.0-3.6 g/kg) of ethanol were tested for differential responses to the aversive effects of 1.0 g/kg ethanol in a conditioned place preference task. Likewise, the effects of 0.3-1.0 g/kg ethanol on spontaneous locomotor activity over a 30-min period, as well as the loss of righting reflex with a higher ethanol dose (3.0 g/kg), were determined in these animals. The LAS rats reacted more aversively to 1.0 g/kg during conditioned place aversion testing than the HAS animals and also had a shorter mean sleeping time following 3.0 g/kg ethanol. Furthermore, dose-related depression of spontaneous motor activity was seen in the HAS animals and not in the LAS animals over a 30-min period using doses of 0.3, 0.6, or 1.0 g/kg (10% w/v) ethanol. Taken together, the results indicate that the intoxicating sequelae of high ethanol doses, such as ataxia and sedation, may not be correlated with the aversive effects of low ethanol doses.
Schechter M D; Krimmer E C
Psychopharmacology
1992
1905-6
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1007/bf02245271" target="_blank" rel="noreferrer noopener">10.1007/bf02245271</a>
DIFFERENTIAL-EFFECTS OF APOMORPHINE IN 6-HYDROXYDOPAMINE-TREATED AND AGED RATS
Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
Schechter M D; Concannon J T
Psychopharmacology
1984
1984
Journal Article
<a href="http://doi.org/10.1007/bf00427431" target="_blank" rel="noreferrer noopener">10.1007/bf00427431</a>
EFFECT OF PLG ON AMPHETAMINE DRUG DISCRIMINATION IN RATS
Psychiatry; Neurosciences & Neurology; Pharmacology & Pharmacy
Davy S J; Schechter M D
Psychopharmacology
1988
1988
Journal Article or Conference Abstract Publication
n/a
Ethnic and Age Disparities in Patients Taking Long-acting Injectable Atypical Antipsychotics.
antipsychotics; asian americans; duration of untreated psychosis; inpatient psychiatry; long-acting injections; psychopharmacology; racial disparities; schizophrenia
Introduction This study will determine whether different ethnicities and different age groups receive equal amounts of long-acting atypical antipsychotics in comparison to their oral equivalents. Methods Secondary analyses of data from the Los Angeles County Department of Health Services Electronic Health Record (total N=63,134 inpatient visits) were performed. Chi-squared statistics were used to compare ethnicity and age with the use of either risperidone injectable or paliperidone palmitate (r-LAIs) versus risperidone oral. Results Among the 63,134 total inpatient visits, there were 3,011 patient visits that included the use of an atypical antipsychotic. Of these 3,011 visits, 452 (15.0%) were on r-LAIs and 2,559 (85.0%) were on risperidone oral. No statistically significant disparities were identified with the use of r-LAIs as compared to oral risperidone amongst ethnic groups (chi-square = 0.88, df = 3, p = 0.831). However, there was a statistically significant difference with the use of r-LAIs as compared to oral Risperidone amongst age groups, favoring younger patients (chi-square = 13.46, df = 3, p \textless 0.004). Conclusion Our data indicate a lack of ethnic disparities in prescribing long-acting atypical antipsychotics and an increased percentage of younger patients being treated with atypical depot antipsychotics over their oral equivalents.
Soleman Mateen; Lam Nikki; Woo Benjamin K
Cureus
2017
2017-10
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.7759/cureus.1772" target="_blank" rel="noreferrer noopener">10.7759/cureus.1772</a>
HPLC EVALUATION OF TET-INDUCED NEUROCHEMICAL CHANGES INVIVO - CORRELATION WITH BEHAVIORAL OBSERVATIONS
Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
Ting Y L T; Fountain S B; Teyler T J
Psychopharmacology
1988
1988
Journal Article
n/a
Increased drug sensitivity in the drug discrimination procedure afforded by drug versus drug training.
Male; Animals; Rats; Amphetamine/pharmacology; Discrimination Learning/*drug effects; Discrimination (Psychology)/*drug effects; Norfenfluramine/pharmacology; Reinforcement Schedule; Pentobarbital/pharmacology; Dose-Response Relationship; Drug; Inbred Strains
Rats were trained to discriminate norfenfluramine (NF) 1.4 mg/kg from its vehicle or amphetamine (AMPH) 0.8 mg/kg or pentobarbital (PB) 6.0 mg/kg in order to determine the role that drug combination training plays in the rate of learning and sensitivity to lower drug doses. The results suggest that drug versus drug training can increase the rate of drug discrimination learning for some drugs that are learned slowly when trained in a drug versus vehicle training procedure, whereas drug versus drug training does not increase the rate of learning for other drugs that are learned rapidly. Drug versus drug training does, however, appear to increase the level of stimulus control of the training drug for all drugs examined in this study.
Boja J W; Schechter M D
Psychopharmacology
1990
1905-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1007/bf02245925" target="_blank" rel="noreferrer noopener">10.1007/bf02245925</a>
Interaction Between Discrimination Of Drug States And External Stimuli
Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
Duncan P M; Phillips J; Reints J; Schechter M D
Psychopharmacology
1979
1979
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1007/bf00426820" target="_blank" rel="noreferrer noopener">10.1007/bf00426820</a>
IS INCREASED CUE SENSITIVITY OF THE DRUG VS DRUG DISCRIMINATION DUE TO AROUSAL OR PHARMACOLOGICAL DIFFERENCES
Psychiatry; Neurosciences & Neurology; Pharmacology & Pharmacy
Boja J W; Schechter M D
Psychopharmacology
1988
1988
Journal Article or Conference Abstract Publication
n/a
Psychopharmacology in the Elderly: Why Does Age Matter?
A growing percentage of the population is aging, with a large subset of this group meeting criteria for one or more neuropsychiatric disorders. Generally, physiological changes due to aging affect most of the pharmacokinetic processes in the body, with age-related physiologic changes in cardiovascular, gastric, hepatic, and renal function leading to changes in the pharmacokinetics of medications that can affect the absorption, distribution, accumulation, and clearance and elimination of various medications. This article aims to discuss the common pharmacodynamic and pharmacokinetic changes associated with physiologic aging and their impacts on the use of psychotropic medications in the elderly.
Kripa Balaram
Psychiatr Clin North Am
. 2022 Dec;45(4):735-744. doi: 10.1016/j.psc.2022.07.004. Epub 2022 Oct 14.
2022
English
Rats become acutely tolerant to cathine after amphetamine or cathinone administration.
Male; Animals; Rats; Drug Tolerance; Discrimination (Psychology)/drug effects; Psychotropic Drugs/*pharmacology; Thiazepines/pharmacology; Antipsychotic Agents/pharmacology; Alkaloids/*pharmacology; Amphetamine/*pharmacology; Phenylpropanolamine/*pharmacology; Dose-Response Relationship; Drug; Inbred Strains
The drug discrimination paradigm was used to evaluate in rats the ability of the discriminate response to either 0.8 mg/kg d-amphetamine or 0.8 mg/kg l-cathinone to generalize to 2.4-6.0 mg/kg of the active cathinone metabolite d-norpseudoephedrine, also known as cathine. When tested 24 h after vehicle administration, cathine generalized in a dose-related fashion in rats (n = 6) trained with cathinone (ED50 = 3.03 mg/kg) and in rats (n = 8) trained with amphetamine (ED50 = 2.93 mg/kg). In contrast, when cathine was tested 24 h after the administration of either amphetamine or cathinone, it produced significantly decreased discriminative performance. The possibility that this acute tolerance may have been produced by release, and subsequent depletion, of brain dopamine was tested by pretreating rats with the dopamine release inhibitor CGS 10746B. When CGS 10746B was administered prior to cathinone it significantly decreased cathinone discrimination. In addition, acute tolerance to cathine at 24 h after vehicle-cathinone co-administration was reversed when cathine was tested 24 h after CGS 10746B-cathinone co-administration. The results suggest that cathinone-produced discriminative stimulus, as well as the acute tolerance to cathine, may be dopaminergically mediated.
Schechter M D
Psychopharmacology
1990
1905-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1007/bf02253729" target="_blank" rel="noreferrer noopener">10.1007/bf02253729</a>
The discriminative properties of the D1 dopamine agonist dihydrexidine in the rat.
Amphetamine/pharmacology; Animals; Apomorphine/pharmacology; Benzazepines/pharmacology; Cocaine/pharmacology; Discrimination (Psychology); Dopamine Agonists/pharmacology; Dopamine D1/*agonists; Dose-Response Relationship; Drug; Male; Phenanthridines/*pharmacology; Rats; Receptors; Sprague-Dawley
The objective of this study was to train rats to discriminate the interoceptive stimuli produced by a selective dopamine D1 agonist. Fourteen male Sprague-Dawley rats acquired the discrimination of the fully effective, high potency, D1 agonist dihydrexidine (DHX) within 20 sessions using a training dose of 3.0 mg/kg. DHX (0.75-4.5 mg/kg) dose-dependently increased DHX-appropriate responding with an ED50 = 1.44 mg/kg. The selective D1 agonist SKF 38398 (2.0-8.0 mg/kg) dose-responsively generalized with an ED50 = 3.54 mg/kg; significantly less potent than DHX. The selective D1 antagonist SCH 23390 (0.06-0.12 mg/kg) dose-responsively decreased DHX-appropriate discriminative performance. These data would indicate that DHX is a selective D1 agonist that may allow for testing of the selectivity of other putative D1 agonists in this experimental procedure. Administration of non-selective dopaminergically active drugs, including apomorphine, amphetamine and cocaine, were each shown to produce intermediate
Schechter M D
Psychopharmacology
1995
1995-05
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1007/bf02246057" target="_blank" rel="noreferrer noopener">10.1007/bf02246057</a>